search
Back to results

Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer

Primary Purpose

Colonic Neoplasms

Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
XELOX or FOLFOX chemotherapy
Sponsored by
Fudan University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colonic Neoplasms focused on measuring Colonic Neoplasms, Laparoscopic Surgery, Neoadjuvant chemotherapy, T4

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Able to provide written informed consent
  • Histologically confirmed diagnosis of colon carcinoma
  • CT or MRI verified as T4 colon cancer without involvement of other organs.
  • Without multiple lesions other than carcinoma in situ
  • Tumor size < 8 cm
  • No bowel obstruction
  • Sufficient organ function
  • No history of gastrointestinal surgery
  • 18 years of age or older
  • Performance Status (ECOG) 0, 1 or 2, life expectancy > 12 weeks
  • Operable patients
  • Completion of neoadjuvant systemic chemotherapy

Exclusion Criteria:

  • Women who are pregnant (confirmed by serum b-HCG in women of reproductive age) or breast feeding
  • No intention to finish neoadjuvantive systemic therapy
  • Unstable or uncompensated respiratory or cardiac disease
  • Serious active infections
  • Hypersensitivity to capecitabine/fluorouracil or oxaliplatin
  • Stomatitis or ulceration in the mouth or gastrointestinal tract
  • Severe diarrhea
  • Peripheral sensory neuropathy with functional impairment

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    Laparoscopic surgery

    Neoadjuvantive chemotherapy + Laparoscopic surgery

    Arm Description

    Patients with T4 colon cancer receive laparoscopic surgery only.

    Patients with T4 colon cancer receive neoadjuvantive chemotherapy and laparoscopic surgery.

    Outcomes

    Primary Outcome Measures

    Disease free survival
    calculated from the date of surgery to the date of recurrence

    Secondary Outcome Measures

    Overall survival
    calculated from the date of diagnosis to the date of death from any cause
    Adverse events (mortality and morbidity)
    Number of participants with treatment-related adverse events assessed by CTCAE v4.0
    The proportion of completion of laparoscopic surgery
    The number of completion of laparoscopic surgery/the number of participants

    Full Information

    First Posted
    May 2, 2016
    Last Updated
    May 17, 2016
    Sponsor
    Fudan University
    Collaborators
    Shanghai Jiao Tong University School of Medicine, Zhejiang University, Tongji University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02777437
    Brief Title
    Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer
    Official Title
    Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer: A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group Clinical Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2016
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 2016 (undefined)
    Primary Completion Date
    October 2019 (Anticipated)
    Study Completion Date
    October 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Fudan University
    Collaborators
    Shanghai Jiao Tong University School of Medicine, Zhejiang University, Tongji University

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Primary Outcome Measures: Disease free survival Secondary Outcome Measures: Overall survival Adverse events (Mortality, morbidity) The proportion of completion of Laparoscopic Surgery Estimated Enrollment: Oct, 2016 Study Start Date: Oct, 2016 Estimated Study Completion Date: Oct, 2019 Estimated Primary Completion Date: Oct, 2021 Groups/Cohorts Laparoscopic surgery for T4 colon cancers Neoadjuvantive chemotherapy + Laparoscopic surgery for T4 colon cancers
    Detailed Description
    Investigators' previous studies indicated that laparoscopic surgery is feasible in T4 colon cancers with comparable clinical and oncologic outcomes. Laparoscopy may be considered as an alternative approach for T4 colon cancers with the advantage of faster recovery. The survival outcome of T4 colon cancers still dismays clinicians and patients. Preoperative chemotherapy is an attractive concept for locally advanced colon cancer. Optimal systemic therapy at the earliest possible opportunity may be more effective at eradicating distant metastases than the same treatment given after the delay and immunological stress of surgery. Besides, the shrinkage of primary tumor before surgery may reduce the risk of incomplete surgical excision and the risk of shedding of tumor cells during surgery. The aim of the present study is to compare the short-and long-term survival outcomes between laparoscopic surgery alone and laparoscopic surgery with 4 cycles of neoadjuvant chemotherapy for T4 colon cancer as well as the mortality and the morbidity. The number of patients, which needs to get power of 80%, is 1960. The average numbers of patients needs to reach approximately 200, and that of surgical centers needs to reach 10. Arrangements in the preoperative, intraoperative and postoperative period will be in complete accordance with the usual care of the center. The baseline demographics and conditions as well as the perioperative items and the postoperative occurrences will be recorded through a prior designed e-questionnaire. Globally,the disease free survival rate (chemotherapy and surgery), mortality (chemotherapy and surgery), the morbidity (chemotherapy and surgery) and the proportion of completion of laparoscopic surgery of the two surgical strategies will be analized and compared.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Colonic Neoplasms
    Keywords
    Colonic Neoplasms, Laparoscopic Surgery, Neoadjuvant chemotherapy, T4

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2, Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    1960 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Laparoscopic surgery
    Arm Type
    No Intervention
    Arm Description
    Patients with T4 colon cancer receive laparoscopic surgery only.
    Arm Title
    Neoadjuvantive chemotherapy + Laparoscopic surgery
    Arm Type
    Experimental
    Arm Description
    Patients with T4 colon cancer receive neoadjuvantive chemotherapy and laparoscopic surgery.
    Intervention Type
    Drug
    Intervention Name(s)
    XELOX or FOLFOX chemotherapy
    Other Intervention Name(s)
    Xeloda+ OXA or OXA+ 5-FU
    Intervention Description
    4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
    Primary Outcome Measure Information:
    Title
    Disease free survival
    Description
    calculated from the date of surgery to the date of recurrence
    Time Frame
    3-year
    Secondary Outcome Measure Information:
    Title
    Overall survival
    Description
    calculated from the date of diagnosis to the date of death from any cause
    Time Frame
    3-year
    Title
    Adverse events (mortality and morbidity)
    Description
    Number of participants with treatment-related adverse events assessed by CTCAE v4.0
    Time Frame
    3-month
    Title
    The proportion of completion of laparoscopic surgery
    Description
    The number of completion of laparoscopic surgery/the number of participants
    Time Frame
    1-month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Able to provide written informed consent Histologically confirmed diagnosis of colon carcinoma CT or MRI verified as T4 colon cancer without involvement of other organs. Without multiple lesions other than carcinoma in situ Tumor size < 8 cm No bowel obstruction Sufficient organ function No history of gastrointestinal surgery 18 years of age or older Performance Status (ECOG) 0, 1 or 2, life expectancy > 12 weeks Operable patients Completion of neoadjuvant systemic chemotherapy Exclusion Criteria: Women who are pregnant (confirmed by serum b-HCG in women of reproductive age) or breast feeding No intention to finish neoadjuvantive systemic therapy Unstable or uncompensated respiratory or cardiac disease Serious active infections Hypersensitivity to capecitabine/fluorouracil or oxaliplatin Stomatitis or ulceration in the mouth or gastrointestinal tract Severe diarrhea Peripheral sensory neuropathy with functional impairment
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jiong Wu, MD,PhD
    Phone
    0086-21-34610367
    Email
    18918298120@163.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Wei Jin, MD,PhD
    Phone
    0086-21-64175590
    Ext
    25022
    Email
    34865893@qq.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Xinxiang Li, MD,PhD
    Organizational Affiliation
    Fudan University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer

    We'll reach out to this number within 24 hrs